© 2024 The Oncology Institute of Hope and Innovation. All rights reserved.
Ph 3 Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)
Request InformationPh 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer that is is Resistant or Refractory to T-DM1, and/or T-DXd, and/or Tucatinib-containing Regimens.
Request InformationPh 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer with FGFR2b Overexpression (FORTITUDE-102)
Request InformationPh 3 Study of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in ER+/HER2- Early Breast Cancer and an Intermediate-High Risk of Recurrence with Completed Definitive Locoregional Therapy and 2+ years of Standard Adjuvant Endocrine-Based Therapy without Disease Recurrence (CAMBRIA-1 / NSABP B-62)
Request InformationPh 3 Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab versus Investigator’s Choice of Therapy in Stage I-III Triple-negative Breast Cancer with Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)
Request InformationPh 3 Study of Datopotamab Deruxtecan (Dato-DXd) plus Durvalumab and Carboplatin Versus Pembrolizumab plus Platinum-based Chemotherapy for the First-line Treatment of Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (AVANZAR)
Request InformationPh 1b/2 Study LBL-007 (anti-LAG-3) plus Tislelizumab in Combination with Bevacizumab plus Fluoropyrimidine Versus Bevacizumab plus Fluoropyrimidine as Maintenance Therapy in Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Request InformationPh 3 Study of CC-92480 (BMS-986348), Carfilzomib, and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Relapsed or Refractory Multiple Myeloma (RRMM)
Request InformationPh 1/2a Study of DB-1303 in Advanced/ Metastatic Solid Tumors
Request InformationPh 3 Study of Selinexor, Pomalidomide and Dexamethasone (SPd) versus Elotuzumab, Pomalidomide and Dexamethasone (EloPd) in Relapsed or Refractory Multiple Myeloma (RRMM)
Request InformationPh 3 Study of Zimberelimab and Domvanalimab plus Chemotherapy Versus Pembrolizumab plus Chemotherapy for 1L Treatment of Metastatic NSCLC With No EGFR or ALK Genomic Tumor Aberrations
Request InformationORACLE: Observation of ResiduAl Cancer with Liquid biopsy Evaluation
Request InformationPh 3 Study of Eftilagimod Alpha (soluble LAG-3) in HER2-Neg/Low Metastatic Breast Cancer Receiving Paclitaxel
Request InformationPh 2 Study of Customized Ibrutinib Treatment Regimens for Chronic Lymphocytic Leukemia (TAILOR)
Request InformationPh 2 Study of Topically Administered LUT014 (Topical B-Raf Inhibitor) in Metastatic Colorectal Cancer Patients with EGFR Inhibitor Induced Acneiform Lesions.
Request InformationPh 2 Study of Combination Therapies with Adagrasib in Advanced NSCLC with KRAS G12C Mutation
Request InformationPh 2 Study of Asciminib (BCR::ABL1 kinase inhibitor) monotherapy in 2nd and 1st Line Chronic Phase- Chronic Myelogenous Leukemia (ASC2ESCALATE)
Request InformationPh 3 Study of ONC-392 (Anti-CTLA-4 mAb) Versus Docetaxel in Metastatic NSCLC that Progressed on PD-1/PD-L1 Inhibitors
Request InformationPh 1a/1b Study of ONC-392 (Anti-CTLA-4 mAb) Alone and in Combination with Pembrolizumab in Advanced Solid Tumors (Melanoma and NSCLC)
Request InformationPh 1/2 Study of Cemiplimab (Anti-PD-1 Antibody) + BNT116 (Fixvac Lung) Versus Cemiplimab Alone in First-Line Treatment of Advanced NSCLC expressing PD-L1 >50%
Request InformationPh 3 Study of Tiragolumab plus Atezolizumab versus Placebo plus Atezolizumab in completely resected Stage IIB, IIIA, or Select IIIB, PD-L1 positive NSCLC who have received adjuvant platinum-based chemo
Request InformationPh 3 study of Disitamab vedotin plus Pembrolizumab versus Chemotherapy in Previously untreated locally advanced or metastatic HER2+ Urothelial Carcinoma (IHC 1+ and greater)
Request Information"A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined with Pemetrexed Carboplatin in Patients with EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment (HARMONi)"
Request InformationPh 2b Study of ZEN003694 with Enzalutamide versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
Request InformationPh 1 Study of ZN-A-1041 (HER-2 Inhibitor) Enteric Capsules as a Single Agent or in Combination in HER2-Positive Advanced Solid Tumors
Request Information© 2024 The Oncology Institute of Hope and Innovation. All rights reserved.